Article Detail

Home > Article Detail
  • P-ISSN 1010-0695
  • E-ISSN 2288-3339

The anti-oxidative and anti-inflammatory effect of Psoralea corylifolia on Ulcerative Colitis Induced by Dextran Sulfate Sodium in Mice

Journal of Korean Medicine / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2016, v.37 no.4, pp.10-21


  • Downloaded
  • Viewed

Abstract

Objectives: This study was to investigate the anti-oxidative and anti-inflammatory effect of Psoralea corylifolia water extract (PE) on ulcerative colitis which was induced by dextran sulfate sodium (DSS) in mice. Methods: Ulcerative colitis was induced by DSS in male BALB/c mice. The mice were divided into 3 groups. The control group (Ctrl) was not induced ulcerative colitis. The pathological group (CE) was induced the colitis. The experimental group (PT) was administered PE after inducing the colitis. The effects of the PE on ulcerative colitis were evaluated by morphological change in the colon tissue and cells, substance P production, activity of tumor necrosis factor (TNF)-α and nuclear factor (NF)-κB, cyclooxygenase (COX)-2 production, and anti-oxidative activity. Results: In the PT group, PE alleviated hemorrhagic erosion in colon mucosa and infiltration of inflammatory cells in lamina propria mucosae. In the colon of the PT group, COX-2 production was inhibited via regulating the activity of TNF-α and NF-κB p65. PE also had an anti-oxidative effect via activating nuclear factor (erythroid-derived 2)-like 2 (Nrf2). Conclusions: In this study, we found the utility of treatment with PE and the potential of developing a medicine for ulcerative colitis by applying our results. Further investigations for the anti-inflammatory mechanism of PE may be needed

keywords
Psoralea corylifolia, ulcerative colitis, anti-inflammatory, anti-oxidative.


Reference

1

1. Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-85.

2

2. Su C, Lichtenstein GR. Ulcerative colitis. In:Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management. Volume 2. 8th ed. Philadelphia:Saunders, 2006:2499-548.

3

3. Yang SK, Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis. 2001;7:260-70.

4

4. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down?. World J Gastroenterol. 2006;12:6102-08.

5

5. Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007;132:516-26.

6

6. Choi CH, Kim YH, Kim YS, Ye BD, Lee KM, Lee BI, et al. Guidelines for the Management of Ulcerative Colitis. Korean J Gastroenterol. 2012;59(2):118-40.

7

7. Jeen YT, Kim JH. Advances in ulcerative colitis therapy. Korean Journal of Medicine. 2009;76(6):654-60.

8

8. Kim SY, Park JW, Ryu BH. Effects of Auklandia Lappa on Dextran Sulfate Sodium -Induced Murine Colitis. Korean J Orient Int Med. 2013;34(2):134-46.

9

9. Chung JH, Seo HS. The Effcets of Psoraleae fructus Extract on Melanin Synthesis of B16Melanoma Cells. J Korean Oriental Med. 2005;26(3):55-65

10

10. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287(1):G7-17.

11

11. Fazio V. Current status of surgery for inflammatory bowel disease. Digestion. 1998;59(5):470-80.

12

12. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res. 2001;1:480-1.

13

13. Ishiguro K, Ando T, Maeda O, Hasegawa M, Kadomatsu K, Ohmiya N, et al. Paeonol attenuates TNBS-induced colitis by inhibiting NF-κB and STAT1 transactivation. Toxicol Appl Pharmacol. 2006;217(1):35-42.

14

14. Myung NY. The inhibitory effect of Orostachys japonicus on dextran sulfate sodium-induced colitis in mice. Kor J Herbology. 2014;29(4):29-34.

15

15. Gassler N, Rohr C, Schneider A, Kartenbeck J, Bach A, Obermüller N, et al. Inflammatory bowel disease is associated with changes of enterocytic junctions. Am J Physiol Gastrointest Liver Physiol. 2001;281(1): 216-28.

16

16. Melgar S, Engströom K, Jäagervall A, Martinez V. Psychological stress reactivates dextran sulfate sodium-induced chronic colitis in mice. Stress. 2008;11:348-62.

17

17. Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet. 1994;9:1199-206.

18

18. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93(5):705-16.

19

19. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem. 1994;269(7):4705-8.

20

20. van Heel DA, Udalova IA, De Silva AP, McGovern DP, Yoshitaka K, Hull J, et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF-κB transcription factors. Hum Mol Genet. 2002;11(11):1281-9.

21

21. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor κB in inflammatory bowel disease. Gut. 1998;42(4):477-84.

22

22. Baeuerle PA. IκB-NF-κB structure: at the interface of inflammation control. Cell. 1998;95:729-31.

23

23. Groszmann RJ. Hyperdynamic state in chronic liver diseases. J Hepatol. 1993;17(2):S38-40.

24

24. RothkӦtter HJ, Pabst P, Bailey M. Lymphocyte migration in the intestinal mucosa : entry, transit and emigration of lymphoid cells and the influence of antigen. Vet Immunol Immunopathol. 1999;72:157-65.

상단으로 이동

Journal of Korean Medicine